May 14th 2024
During a Case-Based Roundtable® event, Jonathan L. Kaufman, MD, discussed which lines of therapy and at what doses would be appropriate to use selinexor in a patient with relapsed/refractory multiple myeloma in the second article of a 2-part series.
Community Practice Connections™: Real-World Applications of Novel Therapies Across TNBC and Addressing Disparities in Care
View More
6th Annual Precision Medicine Symposium: An Illustrated Tumor Board
October 18-19, 2024
Register Now!
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Selinexor Receives Accelerated FDA Approval for Heavily Pretreated R/R Multiple Myeloma
July 3rd 2019Selinexor has received an accelerated approval from the FDA for use in combination with dexamethasone for the treatment of adult patients with relapsed/refractory multiple myeloma who have received ≥4 prior therapies and whose disease is refractory to ≥2 proteasome inhibitors, ≥2 immunomodulatory agents, and an anti-CD38 monoclonal antibody.
Read More
A Look Back at FDA News from June 2019
July 1st 2019In June 2019, the FDA approved a number of agents many fields, including diffuse large B-cell lymphoma, head and neck squamous cell carcinoma, small cell lung cancer, gastroenteropancreatic neuroendocrine tumors, and multiple myeloma. The FDA also approved the fifth biosimilar for trastuzumab and another biosimilar for bevacizumab across several indications.
Read More
Upfront Daratumumab/Rd Combo Approved by FDA for Transplant-Ineligible Myeloma
June 28th 2019The frontline combination of daratumumab with lenalidomide and dexamethasone has been approved by the FDA for the treatment of patients with multiple myeloma who are ineligible for autologous stem cell transplantation.
Read More
Partial Clinical Hold Lifted for One Venetoclax Trial in Multiple Myeloma
June 24th 2019The FDA has lifted a partial clinical hold placed on the phase III CANOVA trial, which is investigating the combination of venetoclax and dexamethasone in comparison with pomalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma and a transformation (11;14) abnormality.
Read More
Concerning Mortality Increase Seen With Venetoclax/Bortezomib Combo in Phase III Trial
June 21st 2019The combination of venetoclax and bortezomib lead to an increased number of deaths by infection in patients with multiple myeloma in the phase III BELLINI trial, according to data presented at the 2019 EHA Congress. Deaths increased in spite of promising responses data and a high progression-free survival rate.
Read More
Pecora Highlights Major Areas of Investigation in Multiple Myeloma
June 14th 2019Andrew L. Pecora, MD, FACP, CPE, discusses the biggest areas of research in the field of multiple myeloma. Pecora says that there has been a surprising number of advances in the field, with current research mostly focused on 1 of 3 areas.
Watch
Daratumumab Improves Responses, PFS in Newly Diagnosed, Transplant-Eligible Myeloma
June 13th 2019In an interview with <em>Targeted Oncology, </em>Phillipe Moreau, MD, discussed the findings from the phase III CASSIOPEIA trial and the potential role for daratumumab in patients with newly diagnosed multiple myeloma in combination with standard-of-care VTd before SCT.
Read More
Oncology Experts Review Key Updates from the 2019 ASCO Annual Meeting
June 12th 2019<em>Targeted Oncology</em> spoke with experts in attendance at the 2019 ASCO Annual Meeting to review what they believed were some of the biggest takeaways from this year's presentation across the fields of lung cancer, breast cancer, GI cancers, genitourinary cancers, melanoma, and multiple myeloma.
Read More
Risk of Progression Reduced With Isatuximab Triplet in Phase III Multiple Myeloma Trial
June 3rd 2019Progression-free survival was significantly improved with the triplet combination of isatuximab, pomalidomide, and low-dose dexamethasone compared with pomalidomide and dexamethasone alone in patients with relapsed/refractory multiple myeloma, according to findings from the phase III ICARIA-MM trial presented at the 2019 ASCO Annual Meeting.<br />
Read More
Subcutaneous Daratumumab Found Noninferior to IV Formulation in Multiple Myeloma
June 3rd 2019A subcutaneous formulation of daratumumab showed similar efficacy to the original intravenous formulation of daratumumab in the phase III COLUMBA trial of patients with relapsed/refractory multiple myeloma. The subcutaenous flat-dose of daratumumab also showed a reduction in the treatment burden, according to results presented at the 2019 ASCO Annual Meeting.
Read More
Socioeconomic Disparities Influence Survival in Multiple Myeloma
June 2nd 2019According to a study authors performed to call attention to the need to address socioeconomic disparities that influence treatment outcomes, higher incomes and having private insurance were associated with a significantly greater probability of survival for patients with multiple myeloma.
Read More
FDA Grants Priority Review to Daratumumab/VTD Combo in Frontline Multiple Myeloma
May 31st 2019The FDA has granted a priority review designation to a supplemental Biologics License Application (sBLA) for daratumumab (Darzalex) in combination with bortezomib (Velcade), thalidomide (Thalomid), and dexamethasone for the treatment of newly diagnosed patients with multiple myeloma who are candidates for autologous stem cell transplant.
Read More
Risk of Progression Reduced With Lenalidomide in Smoldering Multiple Myeloma
May 16th 2019Lenalidomide induced a 72% reduction in the risk of progression to symptomatic disease in patients with smoldering multiple myeloma at 3 years, according to data from the ECOG E3A06 study, to be presented during the 2019 ASCO Annual Meeting.
Read More
Patient-reported outcomes from the phase III myeloma X trial suggested that although patients with relapsed multiple myeloma who received salvage autologous stem cell transplantation had an initial reduction in quality of life and experienced a greater impact of adverse events, they had better long-term outcomes compared with patients who received nontransplantation consolidation.
Read More
Daratumumab Salvage Therapy Effective in Relapsed Myeloma Following Allogeneic SCT
May 1st 2019Daratumumab salvage therapy demonstrated a 1-year overall survival rate of 90.9% in patients with multiple myeloma who relapsed following allogeneic stem cell transplantation and also failed several posttransplant therapies, according to findings presented at the 2019 European Society for Blood and Marrow Transplantation Annual Meeting.
Read More
Maisel Reviews Treatment Options for Multiple Myeloma in 2 Case Studies
April 4th 2019During a <em>Targeted Oncology </em>live case-based peer perspectives program, Christopher Maisel, MD, recently discussed the treatment options and considerations he makes when treating patients with multiple myeloma.
Read More